Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01699737 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Akros Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 325
- Enrollment target
NCT01699737 is a Phase 2 study that has completed, run by Akros Pharma. The registered enrollment target is 325 participants.
The verdict
NCT01699737, a Phase 2 study, has completed, sponsored by Akros Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 325 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of JTT-851 on diabetes as well as to assess the safety, tolerability, and pharmacokinetics of JTT-851 in type 2 diabetic patients either treated with metformin or treatment-naïve.
Interventions
- DRUG Glimepiride
- DRUG JTT-851
- DRUG Placebo for Active
- DRUG Placebo for comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01699737
The ClinicalTrials.gov registry entry for NCT01699737 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 325 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akros Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Glimepiride is the first listed.
NCT01699737 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01699737 about?
NCT01699737 is a clinical study titled "Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the effect of JTT-851 on diabetes as well as to assess the safety, tolerability, and pharmacokinetics of JTT-851 in type 2 diabetic patients either treated with metformin or treatment-naïve.
What is the current status of trial NCT01699737?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 325 participants. The study started on 2012-09. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01699737?
The interventions under investigation include: Glimepiride (DRUG), JTT-851 (DRUG), Placebo for Active (DRUG), Placebo for comparator (DRUG).
Who is sponsoring clinical trial NCT01699737?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.